41 results about "Sequela" patented technology

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

A traditional Chinese medicine formula for treating blood vessel clogging belongs to the field of traditional Chinese medicine formulas, and comprises the following main raw materials: 29-31 parts of black pearl, 11-13 parts of codonopsis pilosula, 7-9 parts of saffron crocus, 8-10 parts of angelica sinensis, 190-210 parts of leek, 9-11 parts of pseudo-ginseng, 37-43 parts of hawthorn, 95-105 parts of astragalus membranaceus, 18-22 parts of kudzu vine root, 8-10 parts of peach kernel, 8-10 parts of prepared rehmannia root, 9-11 parts of radix rehmanniae, 11-13 parts of white paeony root, 3 parts of red ginseng, 9-11 parts of radix ophiopogonis, 14-16 parts of spina date seed, 11-13 parts of Chinese yam, 14-15 parts of schisandra chinensis, 9-11 parts of polygonum multiflorum, 7-9 parts of cinnamon, 18-21 , 13-15 parts of anise and 12-14 parts of rhizoma polygonati. The traditional Chinese medicine composition has an obvious improvement effect on coronary artery insufficiency, myocardial ischemia, mitral valve, tricuspid valve, aortic valve regurgitation, chronic heart failure, patients needing operation bypass stenting, angina pectoris, myocardial infarction sequelae, cerebral ischemia, cerebrovascular sequelae and other symptoms caused by cardiac insufficiency, the dosage is small, the effect is fast, the cure rate is high, relapse is not prone to occurring, and the traditional Chinese medicine composition is suitable for clinical application. The effects of tonifying qi and activating blood, dredging channels and relieving pain, eliminating phlegm and removing blood stasis, tonifying heart and soothing nerves and the like can be achieved.

A food and medicine component composition, a food and medicine compound medicament, and a preparation method of a food and medicine compound medicament and use thereof are provided. The food and medicine component composition includes 0.5 to 1.5 parts by weight of Red Peony Root; 0.5 to 1.5 parts by weight of Chuanxiong Rhizome; 10 to 15 parts by weight of Hedysarum Root; and 50 to 55 parts by weight of whole raw fish. The food and medicine compound medicament is prepared by the following preparation method: placing the above food and medicine component composition in water, and heating for decoction to obtain the food and medicine compound medicament. The food and medicine compound medicament prepared from the above food and medicine component composition can be used for preparing a drug for treating acute central nervous system injury or a sequela of acute central nervous system injury.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-CoV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS CoV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

This application relates to the technical field of exosome preparation, specifically disclosing a pharmaceutical component for the prevention and treatment of sequelae of cerebral thrombosis, its preparation method, and its application. The pharmaceutical component comprises Exo-miR-17-92 and Exo-miR-30d-5p; it is obtained by secretion from mesenchymal stem cells capable of simultaneously overexpressing the genes miR-17-92 and miR-30d-5p; the sequence of the gene miR-17-92 is shown in SEQ ID NO:1, and the sequence of the gene miR-30d-5p is shown in SEQ ID NO:2. The pharmaceutical component of this application, comprising Exo-miR-17-92 and Exo-miR-30d-5p, exerts a significant and excellent therapeutic effect on sequelae of cerebral thrombosis through the synergistic effect of their expression products.

To provide broad spectrum molecules with the capability of binding specifically to and inhibiting TLR-4 and that are useful as therapeutic agents against a broad range of diseases and conditions related to the overexpression or overactivation of TLR-4.SOLUTION: Provided is an aptamer for use in ameliorating or improving at least a symptom or sequelae of acute cardiac infarction, the aptamer having a length between 40 and 100 nucleotides and being selected from a specific sequence group, and (i) the aptamer specifically binding to an epitope on the extracellular domain of TLR-4, (ii) binding of the aptamer to the epitope reducing and / or inhibiting TLR-4 activation, and the aptamer being administered during, prior, or immediately after the acute cardiac infarction.SELECTED DRAWING: None

Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and / or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission. Further contemplated compositions and methods are presented to be effective to prevent and / or reduce severity of sequelae of glutamate excitotoxicity.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating sequelae of a damp-heat stasis type pelvic inflammatory disease and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from traditional Chinese medicinal materials such as hairyvein agrimony, angelica sinensis, rhizoma smilacis glabrae, cortex phellodendri, zaocys dhumnade, salvia miltiorrhiza, herba lycopi and vinegar-processed bupleurum yunnanense according to a certain weight ratio, wherein the hairyvein agrimony serves as a monarch The traditional Chinese medicine composition can synergistically regulate inflammatory response, reduce the level of proinflammatory factors, improve the expression of anti-inflammatory factors, improve the immune state of a body, remarkably improve local blood perfusion of pelvic cavity and promote repair of a uterus tissue structure. Compared with antibiotic drugs, the traditional Chinese medicine composition disclosed by the invention has more outstanding technical effects in the aspects of improving pelvic blood flow and repairing tissues, and also has a good protection effect on uterine epithelial cells in an inflammatory state. The invention further provides enema liquid prepared from the traditional Chinese medicine composition, a rectal administration preparation and application of the enema liquid and the rectal administration preparation. The traditional Chinese medicine composition provided by the invention is good in safety and clear in action mechanism, can be used for preparing related medicines for preventing and treating damp-heat stasis type pelvic inflammatory disease sequelae, and has a good application prospect.

The invention relates to a construction method of an infectious disease patient sequelae risk prediction model. The method comprises the following steps: determining all associated indexes of infectious disease patient sequelae risk prediction; determining weight values of all the associated indexes, and selecting the associated indexes of which the ranking of the weight values is higher than a ranking threshold value from all the associated indexes as prediction index data; carrying out infectious disease patient sampling based on the prediction index data to obtain a sampling data set, wherein the infectious disease patient sampling refers to sampling of patients with sequelae and patients without sequelae in infectious disease patients; obtaining prediction index data of a to-be-predicted infectious disease patient; and performing sequelae risk prediction on the prediction index data of the to-be-predicted infectious disease patient based on the sampling data set to obtain a sequelae risk prediction result. According to the mode provided by the invention, on one hand, a patient can be prevented from frequently going to a hospital to see a doctor so as to save time cost of a user, and on the other hand, the calculated sequelae risk prediction result is more comprehensive and accurate.

The invention discloses an application of cooperation of a chairsi acupoint and acupuncture in facial paralysis catgut embedding intervention, relates to the technical field of traditional Chinese medicine acupuncture treatment, and aims at solving the problems that in existing facial paralysis treatment, the acupuncture stimulation time is short, catgut embedding is mostly suitable for the late stage, hormone dependence is caused, and the sequelae risk is high. According to the application, early-stage facial paralysis patients are screened, facial local acupoint acupuncture is firstly carried out to quickly relieve symptoms, then far-end acupoints of the board Qi acupoints are selected, medical catgut is adopted for acupoint catgut embedding, and the synergistic effect of short-term acupuncture intervention and long-acting catgut embedding stimulation is achieved. Clinical tests prove that the synergistic application can significantly prolong the acupoint stimulation duration, regulate channel qi, stimulate healthy qi, effectively improve the facial nerve function and body and social life functions (facial disability index score) of a patient, shorten the treatment course, reduce the hormone use amount and use time, and reduce the occurrence probability of intractable facial paralysis. The catgut is free of toxic and side effects, convenient to operate and high in patient compliance, a novel traditional Chinese medicine suitable technology is provided for early intervention of facial paralysis, social and economic benefits are remarkable, and the catgut is suitable for clinical popularization.

The system and terminal equipment for disease detection based on physiological parameters, the system comprises: a terminal equipment and a wearable device. Based on the physiological data collected by the wearable device worn by the user daily, the terminal equipment processes the data after obtaining the data, compares the differences between the physiological data of the day and the personal baseline data of the user, monitors the risk of the user's illness of the day every day, obtains the monitoring result of each day and shows it to the user, for example, including: the probability of illness of the day, the risk level of the day, whether there is an abnormality of each physiological parameter of the day, etc. Moreover, combined with the historical monitoring results and historical physiological data, according to the differences of the physiological data of the user before and after the disease, whether there is a long-term sequelae after the recovery of the disease is informed to the user, the long-term trend analysis of the health of the user is realized. Thus, both the current disease risk of the user and the long-term trend analysis of the health of the user are monitored, so as to better provide the health guidance service for the user.

The invention discloses a comprehensive medicine bag for treating traumatic injuries, rheumatism bone diseases and postpartum sequelae and a preparation method thereof, and belongs to the technical field of comprehensive medicine bags, the medicine bag is prepared from the following raw materials in parts by weight: 1 part of white flower, 1 part of red bud flower, 1 part of sambucus williamsii, 1 part of cinnamomum camphora, 1 part of hematoxylon, 1 part of Chinese sausage leaves, 1 part of ruellia tenuifolia and 1 part of folium artemisiae argyi. The preparation method comprises the following steps: grinding fresh leaf branches or dry leaf branches of flos lonicerae, red bud flowers, sambucus williamsii, cinnamomum camphora, hematoxylon, folium saussureae leaves, ruellia tenuifolia and folium artemisiae argyi into coarse powder, and then fumigating the medicinal materials at 105 DEG C for 10-20 minutes to obtain the product. The formula can be used for treating traumatic injuries, rheumatism bone diseases and postpartum sequelae. The traditional Chinese medicine composition has the effects of removing wind, promoting blood circulation, relieving pain, tonifying fire, strengthening the body, diminishing swelling, promoting reunion of fractured tendons and bones, treating wind-cold-dampness arthralgia, waist and knee icy pain, cold impotence, various headache symptoms, limb joint spasm and dramatic pain, menstrual disorder, dysmenorrhea, amenorrhea, puerperal fever, clearing away heat and toxic materials, rheumatism limb joint swelling and pain, traumatic injury, rheumatism arthralgia and myalgia, edema, postpartum anemic fainting, hernia pain, stomachache, rheumatism leg pain and kidney deficiency nephritis. The traditional Chinese medicine composition has the effects of treating postpartum lumbago and thoracoabdominal stabbing pain, promoting blood circulation to treat wounds, clearing and activating the channels and collaterals, regulating blood vessels, improving liver functions, resisting oxidation, promoting digestion, relieving constipation, reducing blood pressure, controlling blood sugar, protecting the liver, beautifying the skin, resisting bacteria and diminishing inflammation, and well improving acnes, comedos and oily skin.

Provided herein are methods and pharmaceutical compositions for preventing or reducing frequency or severity of convulsions or seizures, particularly epileptic seizures by administration of a therapeutically effective amount of 2-deoxy-D-glucose (2-DG) in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones. Also provided are methods and pharmaceutical compositions for reducing severity and progression of traumatic brain injury and deleterious sequelae resulting therefrom in an animal by administration of a therapeutically effective amount of 2-DG in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones.

The present invention discloses a Traditional Chinese Medicine (TCM) splint external fixation device, comprising five dorsal splints, five radial splints, five volar splints, and an ulnar splint for use when the wrist joint is in the neutral, dorsiflexion, flexion, functional, and support positions, respectively. The TCM splint external fixation device of the present invention can adapt to changes in wrist fracture classification and staging. It has a modular structure, is simple and quick to use, can improve the comfort of fracture external fixation treatment, and can reduce the occurrence of sequelae such as joint stiffness in the later stages.

Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The systems and methods include applying an electrical impulse transcutaneously through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient. The electrical impulse is sufficient to reduce a number of antibodies associated with blood clotting to reduce a level of blood clotting in the patient. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.

The invention discloses a traditional Chinese medicine composition for treating Bell paralysis sequelae. The traditional Chinese medicine composition is prepared from the following raw material medicines: astragalus membranaceus, angelica sinensis, radix rehmanniae preparata, ligusticum wallichii, parched white peony root, kudzu vine root, cortex albiziae, pawpaw, semen coicis, lycopodium clavatum, caulis spatholobi and angelica dahurica. The invention further discloses a traditional Chinese medicine compound preparation for treating the Bell paralysis sequelae and application of the traditional Chinese medicine composition or the traditional Chinese medicine compound preparation to preparation of medicine for treating the Bell paralysis sequelae. The traditional Chinese medicine composition has a remarkable curative effect on Bell facial paralysis sequelae such as mouth-eye linkage, facial spasm and facial muscle tension and weakness, can remarkably relieve facial tension, relieve mouth-eye linkage, relieve facial spasm and improve the living quality and mental state of a patient, is remarkable in treatment effect, can adjust and add or reduce the formula according to specific diseases, and is free of toxic and side effects. The method has great popularization and application values.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and / or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SARS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity / mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

The composition comprises the following raw materials: pinellia ternate, poria cocos, leech, scorpion, bamboo shavings, ginseng, radix angelicae pubescentis, notopterygium root, safflower, ligusticum wallichii, radix paeoniae alba, gastrodia elata, immature bitter orange, arisaema cum bile and musk, can expand blood vessels, enables blood flow to be smoother, and has the effects of promoting blood circulation and removing blood stasis. The blood in the body of the patient flows smoothly through the medicine, so that the sequelae can be effectively treated; stasis dredging, yang reviving and desertion consolidation are helped to be achieved; and various functions in the body are balanced.

Devices for identifying a concussion subtype of a suspected concussion patient are disclosed. The devices can be used to support classification of concussion patients into subtypes with different prognoses and treatment requirements. Concussion patients can be classified into subtypes based on signals acquired by a device from the patients, such as biosensor signals. The identified concussion subtypes can be associated with etiology, prognosis, and sequelae. Clinicians and concussion patients can benefit from prompt classification, which can support generation of appropriate, personalized treatment and recovery plans, which may in turn support more complete and rapid recovery.

The invention discloses a traditional Chinese medicine compound application device for treating cerebral infarction sequelae, and belongs to the technical field of medical auxiliary treatment equipment. Comprising an arc-shaped ring, a tablet clamping groove is formed in the arc-shaped ring, a medicine feeding groove is formed in the upper surface of the interior of the tablet clamping groove, a fixing soft belt is fixedly connected to the right side of the arc-shaped ring, a penetrating opening is formed in the lower portion of the right side of the arc-shaped ring, and the fixing soft belt penetrates through the penetrating opening and extends to the outer side; the arc-shaped ring is attached to the arc-shaped contour of the human body application part, the skin can be tightly attached, the gap between the arc-shaped ring and the skin is reduced, and a foundation is laid for subsequent fixation. During fixation, the fixing soft belt is pulled to penetrate through the penetrating opening, the wedge-shaped clamping block on the clamping block with the hole is automatically clamped into the vertical groove of the fixing soft belt under the action of the elastic force of the spring, preliminary limiting is achieved, the tightness of the fixing soft belt can be adjusted according to the body type and the application position of a patient, and the use requirements of different patients are met.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. In some embodiments, the claimed methods can be performed in the absence of added or supplemental oxygen levels, which can be advantageous in some applications.

The invention relates to a medicine for treating cerebral thrombosis, cerebral thrombosis precursor and cerebral thrombosis sequelae. Comprising the following raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae rubra, 10-20 parts of gastrodia elata, 2-5 parts of scorpion, 10-20 parts of pseudo-ginseng, 10-20 parts of rhizoma corydalis, 10-20 parts of radix clematidis, 10-20 parts of earthworm, 10-20 parts of honeysuckle stem, 10-20 parts of ginkgo leaf, 1-3 parts of centipede, 10-20 parts of cassia twig, 2-5 parts of leech and 10-20 parts of herba siegesbeckiae. The traditional Chinese medicine is orally taken and externally applied, and has the effects of dispersing blood stasis, relieving spasm, activating blood, relieving pain, tonifying qi and nourishing blood.

The invention belongs to the technical field of medicines, and particularly discloses an application of IEM-1925 and pharmaceutically acceptable salts thereof in preparation of medicines for treating epileptic status and brain injury caused by nerve toxic agents. In-vivo animal experiments prove that the IEM-1925 is applied after soman poisoning, behavioral epilepsy and electroencephalogram epilepsy can be effectively terminated, neuronal death and neuroinflammation in a hippocampal region can be remarkably relieved, and the long-term cognitive function and anxiety-like behaviors of poisoned living animals can be improved. The curative effect of the medicine is obviously superior to that of the existing standard medicine diazepam in the aspects of epilepsy control, brain injury protection and sequelae improvement. The application range of the IEM-1925 is expanded, the provided medicine is simple in preparation process and low in cost, has good clinical application prospects and market value, provides a brand-new and efficient neuroprotective medicine for treating nerve poison poisoning, and has great medical and public safety value.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.

The present application relates to a kind of traditional Chinese medicine composition and its preparation method, purposes, belong to the field of traditional Chinese medicine.The traditional Chinese medicine composition is prepared from radix paeoniae alba, salvia miltiorrhiza, caulis et ramus youngia, rhizoma sinodendri, liquorice, cornus officinalis, chaenomelis fruit and gentiana macrophylla 8 raw medicinal materials.The composition of the present application is assisted by compatibility of several drugs, synergistic effect, can dredge meridian, tonify liver and kidney, invigorate spleen and stomach, stop arthralgia, suitable for the treatment of increased muscle tension.The results of pharmacodynamic experiment show that the composition of the present application can significantly improve the symptoms of increased muscle tension caused by post-stroke sequelae, spinal cord injury and the like.